MiR-133a could suppress hepatocellular carcinoma (HCC) by targeting Fos-related antigen 2 (FOSL2) and inactivating TGF-β/Smad3 signaling pathway. The gene discussed is FOSL2; the disease is hepatocellular carcinoma.